AzTrials
AzTrials

Pancreatic Cystic LesionsNCT01711294

Evaluation of PCLs Using Three EUS-FNA Needles

A study testing 19 G Flex Needle, 22 G Needle and 19 G Needle in people with Pancreatic Cystic Lesions, run by Boston Scientific Corporation at 8 sites in 3 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

To document impact of EUS-FNA needle size and flexibility on effectiveness of pancreatic cystic lesions (PCL) aspiration, on ability to obtain sufficient material for standard diagnostic testing, and on diagnostic accuracy of EUS-FNA aspirate for differentiation of mucinous (pre-malignant) and non-mucinous cysts. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Pancreatic Cystic Lesions
What is being tested?
19 G Flex Needle, 22 G Needle and 19 G Needle
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
250 participants
Where
8 sitesin 3 countries
Study dates
8 Jan 2013to 18 Dec 2019
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Pancreatic cystic lesion measuring 13mm or greater in largest diameter.
  • Indicated for EUS evaluation of the PCL including EUS-FNA.
  • Age 18 years of age or older.
  • Willing and able to comply with the study procedures and provide written informed consent form to participate in the study.

Who cannot join

  • Cysts in which FNA is not indicated based on review by the clinician, including potential concern of blood vessel location relative to the cyst.
  • Requirement for anticoagulation using clopidogril, warfarin, or other long acting antiplatelet agents (with the exception of aspirin) that cannot be safely stopped according to institutional guidelines.
  • Standard contraindications for EUS.
  • Known pancreatic pseudocyst.
  • Pregnancy.

Trial locations and contacts

8 sites in 3 countries.

8 sites in 3 countries

United States6 sites
  • Massachusetts General Hospital

    Boston, Massachusetts, 02114

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215

  • Indiana University Medical Center

    Indianapolis, Indiana, 46202

  • Mayo Clinic

    Jacksonville, Florida, 32224

  • New York Presbyterian Hospital/Columbia University Medical Center

    New York, New York, 10032

  • Mayo Clinic

    Scottsdale, Arizona, 85259

Other trials in United States

China1 site
  • Changhai Hospital

    Shanghai, 200433

Other trials in China

India1 site
  • Asian Institute of Gastroenterology

    Hyderabad, 500 082

Other trials in India

About this study

Official title: A Multicenter, Prospective, Randomized Study on Endosonographic Evaluation of Pancreatic Cystic Lesions Using 22 G, 19 G, and Flexible 19 G Fine Needle Aspiration

To document impact of EUS-FNA needle size and flexibility on effectiveness of pancreatic cystic lesions (PCL) aspiration, on ability to obtain sufficient material for standard diagnostic testing, and on diagnostic accuracy of EUS-FNA aspirate for differentiation of mucinous (pre-malignant) and non-mucinous cysts.

Being tested
19 G Flex Needle, 22 G Needle, 19 G Needle
Keywords
Pancreatic Cystic Lesions, PCL, EUS-FNA

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 19 G Flex NeedleDevice

    Fine Needle Aspiration of PCL with a 19 G Flex needle. If unsuccessful, a salvage procedure will be done with 19 G or 22 G needle.

  • 22 G NeedleDevice

    Fine Needle Aspiration of PCL with a 22 G needle. If unsuccessful, a salvage procedure will be done with 19 G Flex needle.

  • 19 G NeedleDevice

    Fine Needle Aspiration of PCL with a 19 G needle. If unsuccessful, a salvage procedure will be done with 19 G Flex needle.

Study groups in NCT01711294
Study groupRoleWhat they receive
19 G Flex NeedleActive comparatorDevice: Expect™ Endoscopic Ultrasound Aspiration Needle (19 G Flex)
Receives: Device: 19 G Flex Needle
22 G NeedleActive comparatorDevice: Expect™ Endoscopic Ultrasound Aspiration Needle (22 G)
Receives: Device: 22 G Needle
19 G NeedleActive comparatorDevice: Expect™ Endoscopic Ultrasound Aspiration Needle (19 G)
Receives: Device: 19 G Needle

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Volume of Aspirated Cyst Fluid as a Function of Estimated Maximal Volume

    Volume of aspirated cyst fluid as a function of estimated maximal volume, based on pre-aspiration EUS measure of cyst diameter (s) (% aspiration of total estimated volume)

    Measured: At procedure (Up to 1 hour)

Secondary outcomes (15)
  1. Number of Patients With Related Adverse Events

    Adverse events related to study procedure or study device were tabulated. Adverse events were assessed from the index procedure up to 30 days post procedure.

    Measured: 30 days

  2. Change in Volume of Cyst Post Initial Procedure Compared to Pre Procedure

    Change value is calculated as cyst volume measured after initial procedure (up to 1 hour) minus volume measured at the beginning of the initial procedure. Volume is measured using the standard geometric formula 4/3 πr³ where r is half the long axis. The volume unit is cc.

    Measured: Procedure (Up to 1 hour)

  3. Number of Participants With Successful Echoendoscopic Fine Needle Aspiration of PCL

    Successful echoendoscopic fine needle aspiration of PCL, defined as complete cyst aspiration (final cyst maximal diameter of less than 5mm) or collection of aspirate adequate to perform two standard assays: cytology and carcinoembryonic antigen (CEA) (sample volume of 3 cc or more)

    Measured: Procedure (up to 1 hour)

  4. Number of Participants With PCL Reached/Penetrated

    Patients whose pancreatic cyst lesion(s) can be reached and penetrated by the EUS-FNA needles.

    Measured: Procedure (Up to 1 hour)

  5. Number of EUS-FNA Needle Passes at Initial Procedure.

    Needle pass defined as needle insertion through needle removal outside the cyst lumen, but not including needle repositioning within a single or multi-compartment cyst.

    Measured: Procedure (Up to 1 hour)

  6. Number of EUS-FNA Needles Used at Initial Procedure.

    Total number of EUS-FNA needles used across all participants at the initial procedure.

    Measured: Procedure (Up to 1 hour)

  7. Time Needed for Aspiration for Each Needle Pass at Initial Procedure.

    Needle pass is defined as needle insertion through needle removal outside the cyst lumen, but not including needle repositioning within a single or multi-compartment cyst.

    Time of needle pass in is time of the first needle puncture into the cyst lumen. Needle pass out is time of removal of needle outside the cyst lumen, or after 10 seconds of failed attempt to aspirate fluid after the last needle re-repositioning in a single or multi-compartment cyst.

    Measured: Procedure (Up to 1 hour)

  8. Time From First Needle Pass in to Last Needle Pass Out at Initial Procedure.

    Needle pass is defined as needle insertion through needle removal outside the cyst lumen, but not including needle repositioning within a single or multi-compartment cyst. Time of first needle pass in is time of the first needle puncture into the cyst lumen. Time of last needle pass out is time of removal of needle outside the cyst lumen at the end of the last fluid aspiration from a single or multi-loculated cyst, or after 10 seconds of failed attempt to aspirate fluid after the last needle re-repositioning in a single or multi-compartment cyst.

    Measured: Procedure (Up to 1 hour)

  9. Number of Needles With Needle Insertion Rated as Excellent/Very Good

    Number of needles rated either Excellent or Very good when inserted into the echoendoscope at the initial procedure.

    Measured: Procedure (Up to 1 hour)

  10. Number of Needles With Needle Removal Rated as Excellent/Very Good

    Number of needles rated either Excellent or Very good when removed from the echoendoscope at the initial procedure.

    Measured: Procedure (Up to 1 hour)

  11. Number of Needles With Needle Visualization Rated as Excellent/Very Good

    Number of needles rated either Excellent or Very good for visualization at the initial procedure.

    Measured: Procedure (Up to 1 hour)

  12. Number of Participants With Accurate Diagnosis of the Disease State Using the EUS-FNA Needles

    In order to assess the accuracy of EUS-FNA-based standard assays (cytology and CEA) as a diagnostic measure of disease state, the Disease State per EUS-FNA measure was compared to a reference diagnosis. The reference diagnostic standard was diagnosis from a surgical specimen histology, the true gold standard for cases that evolved to surgical resection within the follow-up of the study. For cases that did not progress to surgery within the follow-up period, the reference diagnostic standard was a composite diagnosis by a consensus board. The consensus board consisted of 3 experts who were blinded to the type of needle used. The consensus board diagnoses of disease state were based on baseline medical history, EUS and cross sectional imaging of the cyst, and aspirate characteristics (i.e. aspirate color and viscosity). If the EUS-FNA diagnosis matches with the histopathology or consensus board diagnosis, then the participant will be counted as having accurate diagnosis.

    Measured: up to 2 years

  13. Number of Participants Requiring Post EUS-FNA Patient Management

    Post EUS-FNA patient management required (clinical and/or imaging surveillance, percutaneous drainage, surgical removal).

    Measured: 30 days

  14. Number of Participants Whose Management Decision Was Directly Influenced by the EUS Findings

    Patients whose Post EUS-FNA Management (clinical and/or imaging surveillance, percutaneous drainage, surgical removal) was Directly Influenced by the EUS-FNA findings.

    Measured: Procedure - 30 days after procedure

  15. Rate of Cross-over to Salvage Arm

    In the case of inability to access the pancreatic cystic lesion or to attain complete cyst aspiration, salvage aspiration procedure should be performed. Patients randomized to 19G Flex should undergo a salvage procedure with 22G or 19G needle (needle choice at discretion of physician); patients randomized to 22G or 19G should undergo salvage procedure with 19G Flex needle.

    Measured: Procedure (Immediate)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Oct 2012 (estimated)
  2. Study start8 Jan 2013
  3. Primary completion6 Jun 2017
  4. Study completion18 Dec 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
250 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01711294
Sponsor's protocol ID
90869947
Other IDs
E7084
Status last verified
Jan 2021
First submitted
26 Sep 2012
Last updated
15 Jan 2021
Data monitoring committee
No

Publications

  • Al-Haddad M, Wallace MB, Brugge W, Lakhtakia S, Li ZS, Sethi A, Pleskow D, Nguyen CC, Pannala R, DeWitt J, Raimondo M, Woodward TA, Ramchandani MJ, Jin Z, Xu C, Faigel DO. Fine-needle aspiration of pancreatic cystic lesions: a randomized study with long-term follow-up comparing standard and flexible needles. Endoscopy. 2021 Nov;53(11):1132-1140. doi: 10.1055/a-1311-9927. Epub 2021 Feb 4.

    PubMed 33197941

Questions about this trial

What is this clinical trial studying?

A study testing 19 G Flex Needle, 22 G Needle and 19 G Needle in people with Pancreatic Cystic Lesions, run by Boston Scientific Corporation at 8 sites in 3 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Jan 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 8 sites in United States, China, India. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 12 Nov 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Volume of Aspirated Cyst Fluid as a Function of Estimated Maximal Volume (time frame: At procedure (Up to 1 hour)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01711294, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jan 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in